They assessed tumor control based on PSA levels and American Urological Association (AHU) scores over follow-ups up to ~20 months and concluded that non-adaptive SBRT treatments are successful with manageable toxicity with no need for adaptation, reducing the overall treatment time. The gene discussed is KLK3; the disease is neoplasm.